bluuebunny/crossref_metadata_2025_split huggingface dataset:
Redescription of the adults of Culicoides bancrofti Lee and Reye and C. hornsbyensis Lee and Reye (Diptera: Ceratopogonidae)
Authors: BELLIS GLENN , DYCE ALAN 
Published: January 2024

The Bancrofti species group of the biting midge genus Culicoides Latreille which embraces two species from Australia and Papua New Guinea is revised. A diagnosis for the group along with a first description of adult male C. bancrofti Lee & Reye and redescriptions of female adult C. bancrofti and male and female adult C. hornsbyensis Lee & Reye are presented together with keys for their specific determination.
Increased Cardio-ankle Vascular Index Values in Migraine Patients With Aura
Authors: Can Yusuf , Uçaroğlu Can Nimet , Akçay Çağla , Ulaş Sena Boncuk , Kocayiğit Ibrahim , Kocayiğit Havva , Ağaç Mustafa Tarık 
Published: January 2024

Patients with migraine with aura are at an increased risk of cardiovascular disease. There are limited data on arterial stiffness in migraine patients with aura. The present study evaluated arterial stiffness in these patients using the cardio-ankle vascular index (CAVI). This prospective study included 50 patients with migraine with aura (43 female, mean age 38.9 ± 9.9 years). The patient group was matched for age and gender with 50 healthy individuals with no history of migraine (43 female, mean age 39.3 ± 10.3 years). All patients and control subjects underwent a comprehensive clinical evaluation by an experienced neurologist and were interviewed about their headache histories. There was no significant difference in baseline demographic characteristics and echocardiographic parameters between migraine with aura patients and the control group. Both right and left CAVI values were significantly higher in the patients with migraine with aura (6.5 ± 1.2 vs 6.1 ± 0.7, P = .043 and 6.6 ± 1.2 vs 6.1 ± 0.7, P = .009, respectively). Arterial stiffness is an important mediator of cardiovascular diseases. We found that CAVI, a novel marker of the arterial stiffness, is increased in patients with migraine with aura.
Efficacy and safety of modified Valsalva maneuver for treatment of paroxysmal supraventricular tachycardia: a meta-analysis
Authors: Lu Zhao , Zhu Jieyun , Gao Min , Song Qiuyun , Pan Dongzan , Huang Chunli , Zhu Liangfeng , Shen Yin 
Published: January 2024

Objective To compare the efficacy and safety of the modified versus standard Valsalva maneuver in the treatment of paroxysmal supraventricular tachycardia (PSVT). Methods The PubMed, Embase, Web of Science, CNKI, WanFang Data, and VIP electronic databases were searched to identify studies comparing the modified and standard Valsalva maneuvers in the treatment of PSVT from database inception to 1 May 2023. Two reviewers independently screened the literature, extracted the data, and assessed the risk of bias of all included studies. Results Nineteen randomized controlled trials involving 2527 patients with PSVT were included. The overall rate of cardioversion was higher in the modified than standard Valsalva group (risk ratio [RR] = 1.80, 95% confidence interval [CI] = 1.61–2.01), as was the success rate of cardioversion after a single Valsalva maneuver (RR = 2.05, 95% CI = 1.74–2.41). There was no statistically significant difference in adverse reactions between the two groups (RR = 1.07, 95% CI = 0.82–1.38). Conclusion Current evidence suggests that the modified Valsalva maneuver can significantly improve the success rate of cardioversion in patients with PSVT without increasing adverse reactions. The modified Valsalva maneuver is therefore worth promoting and should be considered as a routine first treatment. INPLASY registration number: 2023100092
Antidiabetic and antioxidant potential of Crocin in high-fat diet plus streptozotocin-induced type-2 diabetic rats
Authors: Asdaq Syed Mohammed Basheeruddin , Mannasaheb Basheerahmed Abdulaziz , Orfali Raha , Shaikh Ibrahim Ahmed , Alshehri Ahmed , Alghamdi Adel , Alrashdi Meshal Mohammed , Almadani Moneer E , Abdalla Faisal Mohammad Ali 
Published: January 2024

Objectives Crocin, the principal water-soluble active constituent of saffron, possesses numerous pharmacological activities. The present investigation examined the potential antidiabetic and antioxidant characteristics of Crocin in rats with type-2 diabetes by administering it orally and intraperitoneally (i.p.). Methods After 2 weeks of a high-fat diet, streptozotocin (STZ) (i.p., 40 mg/kg) was administered to male adult rats to induce type-2 diabetes mellitus. Body weight and fasting blood glucose (FBG) were measured on days zero, weeks 1, and 2. At the end of 2 weeks of drug administration in their respective groups, fasting insulin and glucose levels were estimated, and insulin resistance (HOMA-IR) was determined. Intraperitoneal glucose (IPGTT) and insulin tolerance tests (ITT) were carried out. Histopathological investigation and biochemical parameters were estimated in pancreatic tissues. Results The Crocin (100 mg/kg) treatment has significantly improved body weight, abatement of FBG, fasting insulin, and HOMA-IR. Likewise, Crocin treatment significantly improved the glucose and insulin challenges. We observed a significantly marked elevation in endogenous antioxidant enzymes in Crocin-treated groups. Similarly, Crocin treatment reversed the histopathological changes and restored the normal integrity and function of the pancreas. Conclusion The overall finding indicates that intraperitoneal administration of Crocin demonstrated better control of glycemic level and body weight. Further, it has improved insulin levels in the serum and potentiated antioxidant properties.
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
Authors: Toorop Alyssa A , Noteboom Samantha , Steenwijk Martijn D , Gravendeel Job W , Jasperse Bas , Barkhof Frederik , Strijbis Eva MM , Rispens Theo , Schoonheim Menno M , van Kempen Zoé LE , Killestein Joep 
Published: January 2024

Background: Extended interval dosing (EID) of natalizumab treatment is increasingly used in multiple sclerosis. Besides the clear anti-inflammatory effect, natalizumab is considered to have neuroprotective properties as well. Objectives: This study aimed to study the longitudinal effects of EID compared to standard interval dosing (SID) and natalizumab drug concentrations on brain atrophy. Methods: Patients receiving EID or SID of natalizumab with a minimum radiological follow-up of 2 years were included. Changes in brain atrophy measures over time were derived from clinical routine 3D-Fluid Attenuated Inversion Recovery (FLAIR)-weighted magnetic resonance imaging (MRI) scans using SynthSeg. Results: We found no differences between EID ( n = 32) and SID ( n = 50) for whole brain (−0.21% vs −0.16%, p = 0.42), ventricular (1.84% vs 1.13%, p = 0.24), and thalamic (−0.32% vs −0.32%, p = 0.97) annualized volume change over a median follow-up of 3.2 years. No associations between natalizumab drug concentration and brain atrophy rate were found. Conclusion: We found no clear evidence that EID compared to SID or lower natalizumab drug concentrations have a negative impact on the development of brain atrophy over time.
Effect of sarcopenia on mortality in acute stroke patients receiving endovascular treatment
Authors: Beşler Muhammed Said , Çay Nurdan , Sayın Bige 
Published: January 2024

Background To investigate the effect of sarcopenia on mortality in patients with acute ischemic stroke caused by anterior circulation large artery occlusion who underwent endovascular treatment. Methods Acute ischemic stroke patients (n = 194) treated with mechanical thrombectomy who underwent chest computed tomography between 2019 and 2022 (median age, 69 [interquartile range: 61–77], 95 females, 99 males) were evaluated retrospectively. The cross-sectional area and density of the pectoralis muscle [pectoralis muscle area (PMA) and pectoralis muscle density (PMD)] at the level of the aortic arch and the erector spinae muscle at the T12 level [erector spinae muscle area (ESMA) and erector spinae muscle density (ESMD)] were measured. The association between skeletal muscle parameters and mortality outcomes was investigated using the receiver operating characteristic (ROC) curve and multivariable logistic regression analyses. Results The 90-day mortality rate was 32% in the study population (n = 62). The ROC analysis revealed that ESMD [area under the curve (AUC): 0.765] and PMD (AUC: 0.759) performed best in the prediction of 90-day mortality. In the multivariable logistic regression analysis, PMD [odds ratio (OR): 0.896; 95% confidence interval (CI): 0.846–0.948; p < 0.001], ESMA (OR: 0.929; 95% CI: 0.878–0.983; p = 0.011), and ESMD (OR: 0.947; 95% CI: 0.913–0.983; p = 0.004), but not PMA, were independent risk factors for 90-day mortality. Conclusion PMD, ESMA, and ESMD may be risk factors for 90-day mortality after mechanical thrombectomy for acute ischemic stroke.
Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis
Authors: Liao Junyi , Tang Jia , Jiang Yuanping , Wang Youwen , Ding Jiali , He Yong 
Published: January 2024

Background: With the rise of targeted treatments for asthma, treatment with omalizumab is a new option. Objectives: To assess the improvement of pulmonary function with additional omalizumab treatment in patients (⩾6 years old) with moderate-to-severe allergic asthma. Data sources and methods: Observational studies of randomized controlled trials of add-on omalizumab for the treatment of patients with moderate-to-severe allergic asthma, published from the establishment till August 2022, were retrieved from WAN FANG DATA, PubMed, CNKI, Embase, Cochrane, and Web of Science databases. Data extraction and quality evaluation were performed on the literature that met the inclusion criteria, using RevMan 5.3 to analyze the data. Results: A total of 11 randomized controlled clinical trials were included, involving a total of 3578 patients with asthma, 1856 patients in the omalizumab group, and 1722 patients in the control group. The improvement in Forced expiratory volume in 1 s as a percentage of predicted normal and Forced expiratory volume in 1 s was more pronounced in the omalizumab-treated group [MD = 3.91, 95% confidence interval (CI): 1.89–5.94, p = 0.0002; MD = 0.09, 95% CI: 0.05–0.13, p < 0.0001], while the improvement in Morning Peak expiratory flow rate was not statistically different between the two groups (MD = 3.64, 95% CI: −22.17–29.45, p = 0.78). Conclusion: Additional omalizumab treatment showed some improvement in lung function in patients with moderate-to-severe asthma. Trial registration: PROSPERO ID:CRD42022378498.
Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy: A Double-Blind, Prospective, Multicentric, Randomized, Active and Placebo Controlled, Five-Arm, Clinical Study to Evaluate the Efficacy, Safety, and Tolerability
Authors: Devasia Sheena , Joseph Jinu T. , P.S. Stephena , Koizumi Seiko , Clarke Liz , V.T. Sriraam , Kailas Abhilash Parameswaran , Madhavan Shajil 
Published: January 2024

Objective The various functionalities of collagen peptides have generated a large interest in utilizing the bioactive peptides as a nutritional therapy to ameliorate various physiological degenerative conditions. Collagen peptides are observed to reduce the pain and aligned difficulties with respect to osteoarthritis. Here we report the enhanced ameliorating property of novel high-functional “Wellnex” Type J collagen peptides following a double-blind randomized active and placebo-controlled 5-arm clinical trial ( n = 100) by using it as a nutritional supplement in subjects with knee joint osteoarthritis in comparison with conventional bovine collagen peptides. The efficacy, safety, and tolerability were also studied. Design Dosages of 2.5, 5.0, and 10.0 g of high-functional Type J bovine collagen peptides, 10.0 g of conventional collagen peptides, and 10.0 g of placebo were given to the 5 groups for a period of 90 days. The Western Ontario McMaster Universities Arthritis Index (WOMAC) score, Pain Scale, Quality of Life (QoL), Physician’s Impression of change Score (PICS), serum C-terminal cross-linked telopeptide of type II collagen (CTX-II) levels and Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS) parameters were monitored. Results Type J 2.5 g showed significant improvement in WOMAC, QoL, CTX, and MOAKS and observed to be equivalent to conventional collagen peptide 10-g supplementation in terms of efficacy. Conclusion The two significant outcomes of the study were that Type J 10.0 g, Type J 5.0 g, Type J 2.5 g and conventional collagen peptides 10.0 g supplementation were observed to be beneficial nutraceutical therapies for knee joint osteoarthritis, and Type J 2.5 g supplementation was equivalent to conventional collagen peptides 10.0-g supplementation in terms of efficacy.
Characteristics of primary Sjogren’s syndrome with articular manifestations at initial treatment
Authors: Zhao Lin , Wang Zheng , Xu Mingxi , Xing Yida , Kong Xiaodan 
Published: January 2024

Objectives: Articular manifestations have been reported in 19.3%–53.5% of patients with primary Sjogren’s syndrome. Our aim was to profile the clinical characteristics of Chinese patients with primary Sjogren’s syndrome who presented with articular manifestations at the time of initial treatment. Methods: We conducted a retrospective study of 129 primary Sjogren’s syndrome patients admitted to the second Affiliated Hospital of Dalian Medical University between April 2016 and December 2021 for initial treatment. Clinical and serological features, extra-articular involvement, and initial treatment were compared between primary Sjogren’s syndrome patients with and without articular manifestations. Results: Fifty-seven (44.2%) primary Sjogren’s syndrome patients had articular manifestations (mean age at diagnosis: 53.4 years), of which 42 (73.7%) presented with symmetrical distribution, 21 (36.8%) patients had rheumatoid factor positivity, and 11 (20.0%) patients had anti-cyclic citrullinated peptide antibodies positivity (mean 6.8 RU/mL); imaging examinations showed no signs of structural damage in these patients. The presence of articular manifestations showed positive correlation with anti-cyclic citrullinated peptide antibody level (odds ratio (OR) 1.01, 95% confidence interval (CI): 1.00–1.02; p = 0.049), C-reactive protein level (OR 1.15, 95% CI: 1.10–1.20; p = 0.000), and European League Against Rheumatism Sjogren syndrome disease activity index scores (OR 1.18, 95% CI: 1.11–1.25; p = 0.000). Ninety (69.8%) primary Sjogren’s syndrome patients received hydroxychloroquine therapy. Hydroxychloroquine treatment was significantly less frequently used in articular manifestation patients (35 (70.0%) vs 55 (85.9%); p = 0.038). Conclusions: Symmetrical polyarthritis was the most common clinical manifestation of primary Sjogren’s syndrome patients with articular manifestations in this cohort. Articular manifestations were associated with higher prevalence of C-reactive protein level, and European League Against Rheumatism Sjogren syndrome disease activity index score.
Plumbogaidonnayite, PbZrSi3O9⋅2H2O, a new Pb-member of the gaidonnayite group from the Saima alkaline complex, Liaoning Province, China
Authors: Wu Bin , Gu Xiangping , Gui Xin , Bonnetti Christophe , Rao Can , Wang Rucheng , Wan Jianjun , Song Wenlei 
Published: January 2024

AbstractPlumbogaidonnayite, ideally PbZrSi3O9⋅2H2O, is a new gaidonnayite-group mineral discovered as a secondary product derived from the alteration of eudialyte from the Saima alkaline complex, China. It occurs as aggregates (up to 1 mm) composed of subhedral to anhedral or platy crystals (individually 5–50 μm), associated closely with microcline, natrolite, aegirine, gaidonnayite, georgechaoite, zircon, bobtraillite and britholite-(Ce) in eudialyte pseudomorphs. The crystals are transparent, colourless or light brown with a vitreous lustre. Plumbogaidonnayite is brittle with conchoidal fracture, and it has a Mohs hardness of ~5 and a calculated density of 3.264 g/cm3. It is optically biaxial (+) with α = 1.61(3), β = 1.63(3) and γ = 1.66(4). The calculated 2V is 80°, with the optical orientations X, Y and Z parallel to the crystallographic a, b and c axes, respectively. The empirical formula is (Pb0.70Ca0.17Ba0.01K0.11Na0.01Y0.01)Σ1.01(Zr1.00Hf0.01Ti0.01)Σ1.02Si3.01O9⋅2H2O calculated on the basis of nine oxygen atoms per formula unit and assuming the occurrence of two H2O groups. Plumbogaidonnayite is orthorhombic, P21nb, a = 11.7690(4) Å, b = 12.9867(3) Å, c = 6.66165(16) Å, V = 1018.17(5) Å3 and Z = 4. The nine strongest lines of its powder XRD pattern [d in Å (I, %) (hkl)] are: 6.489 (36) (020), 5.803 (100) (101), 4.661 (27) (021), 4.336 (29) (121), 3.640 (30) (221), 3.114 (79) (112), 2.947 (27) (400), 2.622 (27) (241) and 2.493 (27) (312). Plumbogaidonnayite has a similar spiral chain framework structure with gaidonnayite and georgechaoite, which is composed of SiO4 tetrahedra and ZrO6 octahedra, but with disordered extra-framework sites (cations and H2O groups) characterised by the substitution of 2Na+ (K+)→Pb2+ (Ca2+) + □ (vacancy). The discovery of plumbogaidonnayite adds a new perspective on the cation ordering and heterovalent substitution mechanism in gaidonnayite-group minerals.
Feasibility and preliminary efficacy of different intensities of functional training in elderly type 2 diabetes patients with cognitive impairment: a pilot randomised controlled trial
Authors: Ghahfarrokhi Majid Mardaniyan , Shirvani Hossein , Rahimi Mostafa , Bazgir Behzad , Shamsadini Alireza , Sobhani Vahid 
Published: January 2024

AbstractBackgroundAging and type-2 diabetes (T2D) are the most important risk factors for cognitive impairment and Alzheimer’s disease. Exercise training is an effective, safe, and practical intervention in improving glucose metabolism, physical function, and cognitive disorders. This pilot study investigated the feasibility and preliminary efficacy of high-intensity low-volume (HIFT) vs. low-intensity high-volume (LIFT) functional training in elderly T2D patients with cognitive impairment.MethodsForty-eight elderly T2D patients (31 female, 17 male, age 67.5 ± 5.8 years, MMSE score 18.8 ± 2.6, FBG 209.5 ± 37.9) were randomly assigned to HIFT, LIFT and control groups. Cognitive impairment was diagnosed with MMSE ≤ 23 based Iranian society. The SDMT, CVLT-II, BVMT-R, and Stroop tests were used to evaluated processing speed, learning, memory and attention respectively. Physical fitness tests include: tandem stance and walk test; TUG; 6MWT, 10MWT; SSST; 5TSTS; and hand grip was used to evaluated static and dynamic balance, agility, walking endurance, gait speed, lower limb function and lower and upper body strength respectively. As well as, Biochemical (FBG, insulin, HOMA-IR, HbA1c) and physiological outcomes (SBP, and DBP) were assessed. The HIFT group performed six weeks of functional training (three sessions per week) with 120–125% of the lactate threshold. The LIFT group performed six weeks of functional training (five sessions per week) with a 70–75% lactate threshold. Feasibility, safety, and acceptability of exercise programs were assessed at the end of the study.ResultHIFT showed a higher adherence rate (91% vs. 87.5%), safety, and acceptability compared to LIFT. MMSE and Stroop scores, 6MWT, FBG, insulin, HOMA-IR, HbA1c, SBP, and DBP significantly improved in HIFT (all,P ≤ 0.004) and LIFT (all,P ≤ 0.023). Changes in 6MWT, FBG, insulin, HOMA-IR, and HbA1c in HIFT (all,P ≤ 0.001) and LIFT (all,P ≤ 0.008) were significant compared to the control group. Changes in Stroop scores were significant only in the HIFT group compared to the control group (P = 0.013). SDMT, CVLT-II, BVMT-R, balance test, 10MWT, SSST, TUG and hang grip significantly improved only in HIFT (all,P ≤ 0.038).ConclusionHIFT vs. LIFT is a safe, feasible, and effective approach for improving some aspects of physical, biochemical, and cognitive function in elderly T2D patients with cognitive impairment. This pilot study provides initial proof-of-concept data for the design and implementation of an appropriately powered randomised controlled trial (RCT) of HIFT vs. LIFT in a larger sample of elderly T2D patients with cognitive impairment.Trial registrationRandomized controlled trial (RCT) (Iranian Registry of Clinical Trials, trial registration number: IRCT20230502058055N1. Date of registration: 11/06/2023.
Association between prevalence and severity of chronic kidney disease and employment status: a nationwide study in Korea
Authors: Choi Seoyeong , Jang Suk-Yong , Choi Eunjeong , Park Yu shin 
Published: January 2024

Abstract
Background
The prevalence of chronic kidney disease (CKD) is increasing globally, and understanding the association between CKD and employment status is crucial. This cross-sectional study aimed to investigate the association of CKD with employment and occupation type among patients with CKD.

Methods
We analyzed data from 36,732 Korean adults aged ≥ 30 years, who participated in the Korean National Health and Nutrition Examination Survey between 2014 and 2021. CKD was detected based on the estimated glomerular filtration rate, and the employment status of the participants was classified into distinct categories: full-time permanent employment, unemployment, self-employment, and precarious employment. We analyzed the data using multiple logistic regression.

Results
We observed a significant association between CKD and a higher likelihood of unemployment compared to that in individuals without CKD (odds ratio, 1.70; 95% confidence interval, 1.47–1.96). This association was more prominent in patients with severe CKD. In the multivariable logistic analysis, patients with CKD had a higher likelihood for precarious employment (odds ratio, 1.29; 95% confidence interval, 0.92–1.88), self-employment (odds ratio, 1.3; 95% confidence interval, 0.90–1.88), and unemployment (odds ratio, 2.10; 95% confidence interval, 1.51–2.92) compared to individuals without CKD.

Conclusions
Our study demonstrated that CKD is associated with a higher likelihood of unemployment and engagement in precarious employment. These findings highlight the challenges faced by patients with CKD in obtaining stable employment and emphasize the need for interventions to improve the employment outcomes of individuals with CKD.